



**HAL**  
open science

## Double trouble progressive external ophthalmoplegia and Huntington's disease.

Josef Finsterer, Sinda Zarrouk-Mahjoub

► **To cite this version:**

Josef Finsterer, Sinda Zarrouk-Mahjoub. Double trouble progressive external ophthalmoplegia and Huntington's disease.. *Molecular Genetics and Metabolism Reports*, 2016, 7, pp.77. 10.1016/j.ymgmr.2016.04.004 . pasteur-01450960

**HAL Id: pasteur-01450960**

**<https://riip.hal.science/pasteur-01450960>**

Submitted on 31 Jan 2017

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives | 4.0  
International License



## Correspondence

**Double trouble progressive external ophthalmoplegia and Huntington's disease**


## Keywords:

Mitochondrial DNA  
Huntingtin  
CAG-repeat expansion  
Multisystem  
Trinucleotide expansion disorder  
tRNA

With interest we read the article by Filosto et al. about a 70 yo female with the double trouble chronic progressive external ophthalmoplegia (CPEO) due to the point mutation m.5613T>C in the tRNA(Ala) gene and Huntington's disease (HD) due to a CAG-repeat expansion of 38 in the huntingtin gene [1]. We have the following comments and concerns.

We do not agree with the description of the presented phenotype as CPEO. The patient obviously had multisystem disease manifesting as cognitive impairment, chorea, cerebellar atrophy resulting in dysarthria, dysphagia, and gait disturbance, hypoacusis, neuropathy, and myopathy [1]. Which of these manifestations are attributable to CPEO and which to HD is difficult to decide since the tRNA mutation was described as novel and since all typical clinical manifestations of HD have been also described in MIDs. Chorea for example has been described in MELAS [2], cerebellar atrophy in ponto-cerebellar hypoplasia [3], and cortical atrophy in Leigh-syndrome [4]. Additionally, CPEO due to mtDNA point mutations has been previously reported to manifest as multisystem disease affecting the cerebrum (callosal agenesis, neuropsychological deficits, head tremor, myoclonus) [5,6,7], ears (hypoacusis) [8], eyes (retinopathy) [9], endocrine system (hypogonadism) [10], and the skeletal muscle (myopathy).

Arguments against a manifesting HD are that CAG-repeat expansions of 38 may or may not manifest with prominent HD features, that onset of HD is usually before age 64 y in the thirties or forties, and that MIDs have been reported which mimic HD.

Overall, this interesting case should be re-classified as either CPEO plus or as non-syndromic multisystem MID (mitochondrial multiorgan disorder syndrome (MIMODS)). We also should be informed about investigations of endocrine organs, the gastrointestinal tract, the kidneys, the peripheral nerves, the bones, and the skin to see if there is more extensive subclinical multiorgan involvement. This includes long-term ECG recordings since ventricular arrhythmias may go undetected but nonetheless require appropriate drug or device therapy.

## References

- [1] M. Filosto, G. Lanzi, C. Nesti, V. Vielmi, E. Marchina, A. Galvagni, S. Giliani, F.M. Santorelli, A. Padovani, A novel mitochondrial tRNA(Ala) gene variant causes chronic progressive external ophthalmoplegia in a patient with Huntington disease, *Mol. Genet. Metab. Rep.* 6 (2016) 70–73.
- [2] H. Nakagaki, J. Furuya, Y. Santa, S. Nagano, E. Araki, T. Yamada, A case of MELAS presenting juvenile-onset hyperglycemic chorea-ballism, *Rinsho Shinkeigaku* 45 (2005) 502–505.
- [3] D. Cassandrini, M.R. Cilio, M. Bianchi, M. Doimo, M. Balestri, A. Tessa, T. Rizza, G. Sartori, M.C. Meschini, C. Nesti, G. Tozzi, V. Petruzzella, F. Piemonte, L. Bisceglia, C. Bruno, C. Dionisi-Vici, A. D'Amico, F. Fattori, R. Carozzo, L. Salviati, F.M. Santorelli, E. Bertini, Pontocerebellar hypoplasia type 6 caused by mutations in RARS2: definition of the clinical spectrum and molecular findings in five patients, *J. Inher. Metab. Dis.* 36 (2013) 43–53.
- [4] J. Rujner, W.T. Chruściel, H. Kulczycka, A. Bednarczyk, Leigh disease in a 17-year-old boy, *Wiad. Lek.* 43 (17–18) (1990) 902–904.
- [5] C.H. Liu, C.W. Liou, C.H. Liu, H.C. Kuo, C.C. Chu, C.C. Huang, Chronic progressive external ophthalmoplegia with T9957C mitochondrial DNA mutation in a Taiwanese patient, *Acta Neurol. Taiwanica* 20 (2011) 53–58.
- [6] S. Bosbach, C. Kornblum, R. Schröder, M. Wagner, Executive and visuospatial deficits in patients with chronic progressive external ophthalmoplegia and Kearns-Sayre syndrome, *Brain* 126 (2003) 1231–1240.
- [7] V. Tiranti, F. Carrara, P. Confalonieri, M. Mora, R.M. Maffei, E. Lamantea, M. Zeviani, A novel mutation (8342G→A) in the mitochondrial tRNA(Lys) gene associated with progressive external ophthalmoplegia and myoclonus, *Neuromuscul. Disord.* 9 (1999) 66–71.
- [8] C. Kornblum, R. Broicher, E. Walther, S. Herberhold, T. Klockgether, C. Herberhold, R. Schröder, Sensorineural hearing loss in patients with chronic progressive external ophthalmoplegia or Kearns-Sayre syndrome, *J. Neurol.* 252 (2005) 1101–1107.
- [9] Y. Isashiki, M. Nakagawa, N. Ohba, K. Kamimura, Y. Sakoda, I. Higuchi, S. Izumo, M. Osame, Retinal manifestations in mitochondrial diseases associated with mitochondrial DNA mutation, *Acta Ophthalmol. Scand.* 76 (1998) 6–13.
- [10] H. Topaloğlu, V. Seyrantepe, N. Kandemir, Z. Akçören, M. Ozgüç, mtDNA nt3243 mutation, external ophthalmoplegia, and hypogonadism in an adolescent girl, *Pediatr. Neurol.* 18 (1998) 429–431.

Josef Finsterer

Krankenanstalt Rudolfstiftung, Vienna

Corresponding author at: Postfach 20, 1180 Vienna, Austria.

E-mail address: [fifigs1@yahoo.de](mailto:fifigs1@yahoo.de).

Sinda Zarrouk-Mahjoub

Genomics Platform, Pasteur Institute of Tunisia, Tunisia

8 April 2016